DKMS Mechtild Harf Science Award

Recognizing Outstanding Scientific Work of World-Class Physicians

As a leading organization in the fight against blood cancer and blood disorders, we are deeply committed to saving as many patients' lives as possible through medical and scientific advancement.

We aim to improve treatment outcomes and increase patients' chances of success. In recognition of outstanding scientific research conducted by internationally renowned physicians in the field of stem cell donation and transplantation, DKMS Stiftung Leben Spenden (Foundation for Giving Life) has annually presented the DKMS Mechtild Harf Science Award since 2001. Winners of this prestigious award receive €10,000. By promoting medical progress in this area, we support the development of new and improved therapies that offer patients the best possible chance of long-term survival.

The award honors Mechtild Harf, a mother of two who tragically lost her battle with leukemia. Her husband, Peter Harf, founded DKMS in 1991. Ever since, their daughter Katharina Harf, Chairwoman of the DKMS Foundation Board, has dedicated her life's mission to DKMS and the fight against blood diseases.

Winner 2025

Prof. Chiara Bonini

“We have the techniques and knowledge for gene editing. The next challenge is identifying the right combinations of TCR and tumor specific antigen that will lead to the most effective therapies”

Through more than 20 years of research in gene and cell therapy, MD, Professor of Hematology at University Vita-Salute San Raffaele and Head of the Department of Experimental Hematology at the IRCSS San Raffaele Scientific Institute, Milan, played a key role in the emergence of this field and advanced one of the first therapy projects applied to HSCT: the suicide gene therapy approach, tends to eliminate alloreactive T cells in case of GvHD, while preserving them in the absence thereof. Her team has since expanded the field of cancer immunotherapy, refining TCR and CAR gene transfer techniques. One of Bonini’s major breakthroughs is TCR gene editing, which permanently reprograms T cells for enhanced precision and persistence in targeting cancer cells.

Previous winners

2024: Prof. Dr. Robert Zeiser

"Our analyses showed that blood cancer cells can influence or even disable immune cells using lactic acid. We now aim to investigate precisely how these processes occur. Our goal is to identify new, targeted therapies to prevent serious complications following stem cell transplantation."

Robert Zeiser is Head of the Department of Tumor Immunology and Immune Regulation, and Head of the Zeiser Laboratory at the Department of Internal Medicine I at Freiburg University Hospital. He has contributed groundbreaking insights into the mechanisms of graft-versus-host disease (GvHD) and the graft-versus-leukemia effect. His seminal findings in basic research have led to practice-changing approaches that significantly improve outcomes for transplant patients. This includes the use of ruxolitinib for treating GvHD, now considered standard clinical practice. His research on mechanisms of disease relapse after transplantation – particularly signal transduction pathways and tumor cell metabolism – has enabled targeted therapeutic strategies. Zeiser and his team demonstrated that acute immune reactions after transplantation frequently originate in the intestine, as its barrier function is compromised.

2023: Prof. Dr. Carl H. June

"It is a great honor to be selected for the DKMS Mechtild Harf Science Award. I join the ranks of many other great physicians and scientists who have already received this award. I share with the Harf family the sad story of losing a beloved family member far too soon, so it means a lot to me that we can meet in this way and toast to the future of cancer treatment,” says Dr. June. ”I thank DKMS and my many brilliant colleagues, along with all of the patients and their families who have put their trust in our research."

Carl June is the Richard W. Vague Professor in Immunotherapy, Director of the Center for Cellular Immunotherapies, and Director of the Parker Institute for Cancer Immunotherapy in the Perelman School of Medicine at the University of Pennsylvania. Throughout his distinguished career, the physician-scientist has made significant contributions to the field of immunology, including his pioneering work on the use of T cells in cancer. He was instrumental in the development of chimeric antigen receptor (CAR)-T cell therapy, which has proven remarkably effective in treating patients with relapsed and refractory leukemia and lymphoma. Moreover, his work has not only created a paradigm shift in the treatment of blood cancers, but it also has the potential to improve treatment options for solid cancers, chronic infections, and autoimmune diseases in the future. Already, numerous preclinical and clinical trials are underway, which hold great promise not only for the scientific community, but most importantly for all affected patients and their families.

2022: Prof. Dr. Ricardo Pasquini

“It is a great honor for me to receive the award and I am grateful to be acknowledged by DKMS. I accept this award with deep gratitude to my colleagues, without whom my life’s work achievements would not have been possible,” says Dr. Pasquini.

Ricardo Pasquini is Emeritus Professor of Internal Medicine, Hematology and Oncology at the Federal University of Paraná in Curitiba. He has been the Head of the Department of Internal Medicine and thereafter Head of the Division of Hematology and Medical Oncology at the university hospital for almost 30 years. At the same institution Pasquini successfully established the Bone Marrow Transplant Center that achieved excellence in research and clinical care. Under his direction the center has provided top-level care for patients from diagnosis to treatment and still continues to do so.

In 1993, his team was responsible for the first transplantation of umbilical cord blood stem cells in Latin America, and in 1995 he performed the first transplantation from an unrelated donor in Brazil. Over the course of his long career, the founding member of the Brazilian Society of Bone Marrow Transplantation trained generations of specialists who have become international leaders in their field.

2021: Prof. Dr. Massimo Fabrizio Martelli

“I am sincerely honored by this recognition of my lifelong work, which has been so rewarding in and of itself. Being selected to receive the DKMS Mechtild Harf Science Award 2021 took me completely by surprise. It is with deep gratitude that I accept this prestigious honor and I am overwhelmed to follow in the illustrious footsteps of previous award winners.”

Professor Martelli is an outstanding haematologist, innovative scientist and a pioneer in haploidentical transplantation. His studies on approaches to reduce the risk of graft-versus-host disease while preserving graft-versus-leukemia effects have been enormously fruitful for the further development of medical science in this field. Martelli facilitated successful stem cell transplantations for high-risk patients with acute leukemia without compatible donors and conducted the first successful clinical trial on haploidentical stem cell transplantation in 1993, and to this day his research has had a great impact on the lives of patients with blood cancer. He has been Professor at the University of Perugia and Head of the Department of Oncology and Hematology. During his 30 years at the university, together with a group of brilliant young scientists, Martelli established a department that achieved excellence in research and clinical care.

2020: Prof. Dr. J. H. Fred Falkenburg

“I am truly honored to receive the DKMS Mechtild Harf Science Award – and thus to be among the prizewinners who have dedicated their work and lives to the fight against leukemia. It is an even greater honor to be placed in such distinguished ranks as those of the past honorees, all of whom have made important contributions to improve blood cancer treatment. Furthermore, I am very pleased to help fund research on leukemia, lymphoma and multiple myeloma by donating the prize money to Doelfonds Leukemie van de Bontius Stichting, the Charity Fund of the Department of Hematology at the Leiden University Medical Center (LUMC).”

J. H. Fred Falkenburg is Professor of Hematology and Deputy Head of the Department of Hematology at Leiden University Medical Center (LUMC) and one of the most important researchers in the field of immunotherapy of hematological diseases. The results of research programs on bone marrow transplantation and immunotherapy of hematological malignancies in the Laboratory of Experimental Hematology at LUMC conducted under his direction have been translated into clinical success for the benefit of patients. LUMC has a long history in the treatment of blood cancer and was involved in the first successful bone marrow transplant carried out on a leukemia patient in 1968. Falkenburg has greatly contributed to finding better therapies during his 32 years at the center. In 2018, he was appointed Director of the Dutch Cancer Society.

2019: Stephen J. Forman, MD

Dr. Stephen J. Forman is regarded as one of the most renowned cancer physicians in the US. An international expert in leukemias, lymphomas and stem cell transplants, he heads the Hematologic Malignancies and Stem Cell Transplantation Institute at the City of Hope Comprehensive Cancer Center in Duarte (CA)/USA. During the 32 years he has spent there, he has developed the City of Hope Comprehensive Cancer Center into one of the world’s most successful. To date, the center has hosted over 15,000 stem cell transplants for patients with blood cancer or other life-threatening diseases of the hematopoietic system.

2018: Prof. Dr. Yair Reisner

Prof. Yair Reisner has worked at the Weizmann Institute of Science in Rehovot, Israel, for over 30 years. He has made many groundbreaking contributions toward a better understanding of stem cell transplantation and specialized in transplant immunology, in particular immune tolerance mechanisms in stem cell transplants and cell therapy. The findings of major research projects at the Yair Reisner Lab of the Weizmann Institute of Science have translated into clinical successes and benefited numerous patients.

2017
Prof. Dr. med. Dr. h.c. Dieter Hoelzer (Germany)
Richard Champlin, MD (USA)

2016
Prof. Dr. Katharina Fleischhauer (Germany)

2015
John A. Hansen, MD (USA)

2014
Richard J. O’Reilly, MD (USA)

2013
Dennis L. Confer, MD (USA)
Prof. Dr. Guido Lucarelli (Italy)

2011
Prof. Dr. Karl-Georg Blume (Germany)

2010
Prof. Dr. med. Dr. h.c. mult. Theodor M. Fliedner (Germany)

2009
Rainer F. Storb, MD, PhD (USA)

2008
Jon van Rood, MD, PhD (Netherlands)

2007
Mary M. Horowitz, MD, MS (USA)

2006
Prof. Dr. med. Hans-Jochem Kolb (Germany)

2005
E. Donnall Thomas, MD (USA)

2004
Eliane Gluckmann, MD (France)

2002
Effie Wang Petersdorf, MD (USA)

2001
Dr. Helmut Geiger (Germany)
Anita Waldmann (Germany)